Dendritic cell-based vaccination in cancer: Therapeutic implications emerging from murine models

Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer DC-based vaccine (Sipuleucel-T), there has been a surge of interest in exploiting these cells as a therapeutic option...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mac Keon, S., Ruiz, M.S., Gazzaniga, S., Wainstok, R.
Formato: JOUR
Materias:
Adjuvants
Cancer immunotherapy
Dendritic cell maturation
Dendritic cell subsets
Dendritic cell-based vaccines
Dendritic cells
CD103 antigen
CD11b antigen
dendritic cell vaccine
imiquimod
indoleamine 2, 3 dioxygenase
inducible T cell costimulator
interleukin 2 receptor
ovalbumin
pattern recognition receptor
toll like receptor 7
toll like receptor adaptor molecule 1
tumor necrosis factor alpha
unclassified drug
antigen presenting cell
bone marrow derived dendritic cell
cancer model
cancer therapy
CD8+ T lymphocyte
cytotoxic T lymphocyte
dendritic cell
human
immune response
Langerhans cell
major histocompatibility complex
monocyte
mouse
murine model
neoplasm
nonhuman
phase 1 clinical trial (topic)
plasmacytoid dendritic cell
Review
tumor microenvironment
vaccination
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_16643224_v6_nMAY_p_MacKeon
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

Ejemplares similares

Ejemplares similares